# Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

> **NCT00401401** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 30 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Cancer

## Interventions

- **DRUG:** zalutumumab
- **DRUG:** cisplatin
- **PROCEDURE:** Radiotherapy

## Key facts

- **NCT ID:** NCT00401401
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.
- **Last updated:** 2011-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401401, "Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00401401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*